anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: To evaluate the effects of photodynamic therapy (PDT) in extraction sockets of periodontally compromised molars on soft tissue healing, postoperative pain, bone density and bone height changes. Methods: This study is a single-center, single-blind, randomized controlled superiority clinical trial. Thirty-eight periodontally compromised molars requiring extraction in patients attending the Department of Periodontology, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, from December 2022 to September 2023 were included, and randomly assigned to PDT group and control group. The control group received routine debridement after extraction, while PDT group received routine debridement followed by PDT. The bucco-lingual and mesio-distal wound distances at 7 and 14 d after extraction were measured, and then the wound closure rates were calculated. Evaluating the soft tissue healing indexes at 7 and 14 d after extraction. The visual analogue scale was used to assess the pain level at 6 h, 1 d, 2 d, and 3 d after tooth extraction. Apical radiographs were taken immediately and 2 months after extraction in order to compare the changes of the bone density and height. Results: The wound closure rate at 1 week was (78.08±5.45)% in PDT group and (71.03±6.82)% in control group, with significant differences (P<0.01). The wound closure rate at 2 weeks in PDT group [(85.88±3.84) %] was significantly higher than that in the control group [(81.66±3.79) %] (P<0.01), but did not reach the superiority value of the superiority test (superiority value=10%, 95%CI at 1 week: 3.00%-11.12%, 95%CI at 2 weeks: 1.71%-6.73%). The soft tissue healing index of PDT group at 1 week was significantly better than the control group (P<0.05), but there was no significant difference between the two groups at 2 weeks (P>0.05). There was no significant difference between the two groups in terms of postoperative pain at 6 h, 1 d, 2 d and 3 d as well as in bone density and height changes at 2 months after tooth extraction (P>0.05). Conclusions: PDT could promote soft tissues healing to some extent, but did not provide additional assistance in the healing of extraction sockets of periodontally compromised teeth. PDT did not show benefits on postoperative pain, changes of the bone density and bone height after tooth extraction.
A cosmetic composition comprising 1.0 to 20 wt.% wax; 0.1 to 1.5 wt.% thickener; 1.0 to 15 wt.% emulsifier; 1.0 to 15 wt.% film-forming polymer; 1.0 to 15 wt.% organic polyol; and 1.0 to 90 wt.% water, all in relation to the overall weight of the cosmetic composition, wherein the weight ratio of wax to thickener is from 40:1 to 1:1. The wax may be selected from beeswax, carnauba wax, candelilla wax and paraffin wax. The thickener may be a polymeric organic thickener such as an acrylic acid homopolymer. The emulsifier may be a polyalkoxylated fatty alcohol. The film-forming polymer may be selected from the group of polyvinylpyrrolidones and vinylpyrrolidone/vinylacetate copolymers. The polyol may be selected from the group of propylene glycol, glycerin and panthenol. The composition may comprise 2.0 to 10 wt.% of a lipid differing from the wax such as a mineral oil, natural oil, synthetic oil or mixture thereof. The composition may be in the form of a paste. The composition is for the temporary deformation of keratinous fibers.
The invention relates the HCP. The invention uses mixes the grasshopper protein and complex enzyme. In the complex enzyme, the rate of airbus, neuter protease, polypeptides and basified protease is 2:1:1:1. The enzyme-substrate rate is 2.5-5%, the pH is 7, and the temperature is 50Deg.C for 3-4hours. The HCP contain much active polypeptide. The HCP has the advantages of fatigue resistance, and good hypoxia tolerance property. The product is used in health industry, health food and drugs.
Hutchinson-Gilford Progeria Syndrome (HGPS) is an extremely rare genetic disorder that causes accelerated aging, due to a pathogenic variant in the LMNA gene. This pathogenic results in the production of progerin, a defective protein that disrupts the nuclear lamina's structure. In our study, we conducted a histopathological analysis of various organs in the LmnaG609G/G609G mouse model, which is commonly used to study HGPS. The objective of this study was to show that progerin accumulation drives systemic but organ-specific tissue damage and accelerated aging phenotypes. Our findings show significant fibrosis, inflammation, and dysfunction in multiple organ systems, including the skin, cardiovascular system, muscles, lungs, liver, kidneys, spleen, thymus, and heart. Specifically, we observed severe vascular fibrosis, reduced muscle regeneration, lung tissue remodeling, depletion of fat in the liver, and disruptions in immune structures. These results underscore the systemic nature of the disease and suggest that chronic inflammation and fibrosis play crucial roles in the accelerated aging seen in HGPS. Additionally, our study highlights that each organ responds differently to the toxic effects of progerin, indicating that there are distinct mechanisms of tissue-specific damage.
The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
Glycan ingredient MF4 has increased immunological competence and anti-tumour functions, which is separated from sea-animal thick shell mussel. Its relative molecular weight is 113,000. It was analyzed and identified the physical properties and chemical structure through multiple spectra and methods, of which spectra are such as UV, IR, GC/MS,1HNMR, of which chemical methods are such as hydrolysis, acetylization, periodate oxidation, Smith degradation, methylation, sulfuric acid- carbazole reaction. Testing in vitro proves that MF4 promotes T,B lymph cells proliferation. Anti-tumour testing in vivo shows that small rat with subcutaneous inoculation is capable of inhibiting Lewis lung cancer and S-180 caruncle's growth, and has promotion functions for NK cell activity and lymph cell transfer of charged Lewis lung cance small rat. The thick shell mussel glycan MF4 is used to prepare new immonological strengthen pharmaceutics and anti-tumour drugs. And it's a new approach for developing Chinese sea biological sources.
2134675 9322430 PCTABS00027 The keratin K1 vector for expression of a nucleic acid cassette in the epidermis. The vector has a 5' flanking region of the keratin K1 gene including a 5' flanking sequence, a keratin K1 promoter, 5' transcribed but untranslated region and a first intron and an intron/exon boundary, all in sequential and positional relationship for expression of a nucleic acid cassette. A 3' flanking region in the K1 keratin gene containing regulatory sequences including a 3' transcribed but untranslated region and contiguous noncoding DNA containing the transcriptional termination region. The 3' flanking region and a 5' flanking region are linked by a polylinker having a plurality of restriction endonuclease sites for the insertion of a nucleic acid cassette. The nucleic acid cassette encodes a sequence which can be used to express any protein, polypeptide or antisense RNA. The vector can be inserted both in vivo and ex vivo into epidermal cells. Further, it can be used for making transgenic animals or bioreactors of epidermal cells. The vector has been found useful for gene therapy in treatment of a variety of diseases including skin ulcers, wound healing, surgical incisions, psoriasis and cancer.
Free-living amoebae (FLA) are isolated from the hospital environments and known as Trojan horses for medical essential microorganisms. This study aimed to investigate the prevalence and the presence of FLA and two critical agents of nosocomial infections, in the hospital wards. Sixty samples were collected from four communities and cultured onto non-nutrient agar (NNA). After total DNA extraction, FLA were characterized using PCR and sequencing. The presence of Candida albicans and Staphylococcus aureus was evaluated using real-time and conventional PCR, respectively. Acanthamoeba sp. was characterized in 30 (50%) samples. Two (6.6%) and one (3.3%) samples were positive for Vahlkampfiidae and Vermamoeba vermiformis, respectively . S. aureus was detected in 13 (43.3%) of samples, while none of them were positive for methicillin-resistant gene. C. albicans DNA was detected in one (3.3%) FLA-positive sample. The isolation of FLA from hospital suggests an essential role these eukaryotes in the inter-ward circulation of nosocomial infections.
BACKGROUND: Patients with follicular lymphoma (FL) often relapse or become refractory to treatment (R/R). While the R/R FL treatment landscape evolves, little is known about the priorities of patients and physicians. This discrete-choice experiment (DCE) study assessed patients' and physicians' treatment preferences, and the trade-offs they would be willing to make between efficacy, tolerability, and administration.
METHODS: An online survey was conducted in US-based patients (≥18 years) with R/R FL and FL-treating physicians. The DCE was informed by a targeted literature review, clinical data, expert oncologist input, and pilot interviews. Participants completed eight experimental choice tasks where they chose between two hypothetical treatment profiles defined by six attributes: progression-free survival (PFS), administration/monitoring, risks of laboratory abnormalities requiring intervention, severe infections, diarrhea, and cytokine release syndrome (CRS). Relative attribute importance (RAI) and willingness to trade-off between PFS and other attributes were estimated.
RESULTS: Two-hundred patients (mean age 63.5 years; median three prior lines of therapy) and 151 FL-treating physicians participated. Increasing PFS was most important for both groups, although it was relatively less important to patients than physicians (RAI 35.2% vs. 45.7%). Administration/monitoring was three times more important to patients than physicians (RAI 28.8% vs. 9.5%); patients preferred oral treatment and would be willing to tolerate a significant reduction in PFS for oral administration over weekly intravenous infusions. Avoiding CRS was less important to patients than to physicians (RAI 7.7% vs. 15.8%). Both groups would accept shorter PFS for reduced risks of side effects (especially of laboratory abnormalities for patients and of CRS for physicians).
CONCLUSION: Although PFS was the most important attribute to patients and physicians, both would tolerate lower PFS for reduced side effects. Patients would also accept a substantial reduction in PFS for oral administration. Differences between the preferences/priorities of patients and physicians highlight the importance of shared decision-making.
Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
Preventing bone loss is an important concern for women during post-menopausal period. Menopause significantly speeds bone loss and increases the risk for osteoporosis. This study was to investigate the effectiveness on quality of life (QOL), patient satisfaction in postmenopausal women receiving raloxifene/cholecalciferol combination therapy. In addition, we analyzed adverse events to assess the safety profile of this drug.

This study is a multicenter, prospective, non-critical observational study of women receiving raloxifene/cholecalciferol (raloxifene 60mg + cholecalciferol 800 IU, Rabone D®, Hanmi Pharma, South Korea) combination therapy to treat or prevent postmenopausal osteoporosis. Data will be collected from patients receiving routine treatment at about 105 primary, secondary, or tertiary medical institutions in South Korea. Each subject visits the institution according to the protocol that designed the follow-up visits for six months to examine changes in, and factors influencing quality of life (EQ-5D-5L method), patient satisfaction with efficacy and convenience (questionnaire), and safety. This study will approved by the institutions' IRBs and is in compliance with clinical research ethics regulations.
Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
This is a Phase II, randomized, open-label immunogenicity and safety study of different immunization schedules and delivery systems (syringe and needle vs. the Stratis™) in healthy, vaccinia-naïve adults 18 years to 40 years of age, inclusive. Approximately 352 subjects will be enrolled and randomized to one of four study arms. Study Arm A (N=88) will receive a two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using a syringe and needle on Day 1 and 29. Study Arm B (N=88) will receive a two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using a syringe and needle on Day 1 and 15. Study Arm C (N=88) will receive a two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL) via the SC route using a syringe and needle on Day 1 and 22. Study Arm D (N=88) will receive a two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL) via the SC route using the Stratis™ on Day 1 and 29. Immunogenicity assessments will be performed using ELISA and PRNT. Safety assessments will be done via solicited injection site and systemic reactions. Unsolicited AEs will be collected until 28 days post last injection and SAEs for the duration of the subjects' study participation. Safety laboratory assessments will be performed at baseline and 14 days after each vaccination. Primary outcome measures: For each subject, the peak PRNT will be defined as the highest titer among all available measurements post second vaccination; Occurrence of solicited local injection site reactions in subjects receiving vaccine via the Stratis™ compared to syringe and needle administration as collected on the memory aid and by in clinic assessment. Parent protocol to sub-study 13-0027.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutics and medicine. Crude drug (plant Piper Laetispicum CDC) is selected, preprocessed by slicing or crushing, soaked in an organic solvent or percolated to produce an extract. Or else, crude drug of plant Piper Laetispicum CDC is selected with producing an extract by applying the method of supercritical fluid extraction following preprocessing of the crude drug by slicing or powdering. For prevention and/or treatment of the diseases associated with monoamine mediator metabolism, the extract Piper Laetispicum CDC is produced by said methods. The extract is applied to prepare drugs, biologically active additives and food additives for treatment and/or prevention of (mental) diseases associated with monoamine mediator metabolism. ^ EFFECT: inventions allow producing the extract with higher biological activity and alkaloid content. ^ 11 cl, 12 tbl, 12 ex
The invention discloses a disinfectant for quickly damaging a virus envelope. The disinfectant preparation takes edible acid and cetylpyridinium chloride as main active ingredients, can cause damage to the virus envelope in a very short time, further quickly kill various envelope viruses, and can also kill and inhibit bacteria and fungi. The disinfectant can be divided into external skin disinfectant (such as hand disinfectant) and internal mucosa disinfectant (such as collutory and nasal wash) according to different adjuvants. The disinfectant can also be prepared into liquid and dry powder preparations according to different requirements. The disinfectant preparation has quick and efficient killing effect on various enveloped viruses, bacteria and fungi. In addition, the disinfectant preparation has the advantages of strong stability, no stimulation to human skin, no residue after use, easy water solubility, safety, no toxic or side effect, and suitability for disinfection of daily articles such as oral and nasal mucosa, hand and foot skin, wounds, clothes and the like.
OBJECTIVE: To evaluate dexamethasone prescribing practices, patient adherence, and outcomes by dosing regimen in children with acute asthma discharged from the emergency department (ED).
STUDY DESIGN: Prospective study of children 2-18 years treated with dexamethasone for acute asthma prior to discharge from an urban, tertiary care ED between 2018 and 2022. Demographics, clinical characteristics, ED treatment, and discharge prescriptions were collected via chart review. The exposure was discharge prescription (additional dose) versus no discharge prescription for dexamethasone. The primary outcome was treatment failure, defined as return ED visit, unplanned primary care visit, and/or ongoing bronchodilator use. Secondary outcomes included medication adherence, symptom persistence, quality-of-life, and school/work absenteeism. Outcomes were assessed by telephone 7-10 days after discharge.
RESULTS: 564 subjects were enrolled; 338 caregivers (60%) completed follow-up. Children were a median age 7 years, 30% Black or African American, 49% Hispanic, and 79% had public insurance. A discharge prescription for dexamethasone was written for 482 (86%) children and was significantly associated with exacerbation severity, number of combined albuterol/ipratropium treatments, and longer length of stay. There was no difference in treatment failure between the discharge prescription and no discharge prescription groups (RR 0.87; 0.67, 1.12), including after adjusting for potential confounders; there was no difference between groups in secondary outcomes.
CONCLUSIONS: Prescription for an additional dexamethasone dose was not associated with reduced treatment failure or improved outcomes for children with acute asthma discharged from the ED. Single, ED-dose of dexamethasone prior to discharge may be sufficient for children with mild to moderate asthma exacerbations.
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
A method for retrospective calibration of a glucose sensor uses stored values of measured working electrode current (Isig) to calculate a final sensor glucose (SG) value retrospectively. The Isig values may be preprocessed, discrete wavelet decomposition applied. At least one machine learning model, such as, e.g., Genetic Programming (GP) and Regression Decision Tree (DT), may be used to calculate SG values based on the Isig values and the discrete wavelet decomposition. Other inputs may include, e.g., counter electrode voltage (Vcntr) and Electrochemical Impedance Spectroscopy (EIS) data. A plurality of machine learning models may be used to generate respective SG values, which are then fused to generate a fused SG. Fused SG values may be filtered to smooth the data, and blanked if necessary.
EXALGO is contraindicated in patients with paralytic ileus. Avoid the use of EXALGO in patients with other GI obstruction.

Because the EXALGO tablet is nondeformable and does not appreciably change in shape in the GI tract, EXALGO is contraindicated in patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic, for example: esophageal motility disorders, small bowel inflammatory disease, “short gut” syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel’s diverticulum). There have been reports of obstructive symptoms in patients with known strictures or risk of strictures, such as previous GI surgery, in association with the ingestion of drugs in nondeformable extended-release formulations.

It is possible that EXALGO tablets may be visible on abdominal x-rays under certain circumstances, especially when digital enhancing techniques are utilized.

The hydromorphone in EXALGO may cause spasm of the sphincter of Oddi. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
BACKGROUND: Women experiencing problematic menopausal symptoms report lower health-related quality of life and greater healthcare use than women without symptoms. Not all women want to or are able to take hormone replacement therapy. Strengthening the evidence for menopause symptom-management options, including physical activity, improves agency for women.
AIM: This overview assesses effectiveness of physical activity and exercise interventions targeting women experiencing menopause symptoms.
METHODS: Medline, Embase, CINAHL, Scopus, The Cochrane Database of Systematic Reviews and Social Science Citation Index were searched (June 2023) for systematic reviews of physical activity and exercise interventions targeting women experiencing menopause. Reviews were assessed using AMSTAR-2 and a best-evidence approach to synthesis without meta-analysis (SWIM) was adopted. The protocol was registered on PROSPERO (CRD42022298908).
RESULTS: Seventeen reviews included 80 unique relevant primary studies with 8983 participants. There is evidence showing improvement of physical, urogenital, and total symptoms following yoga interventions. Evidence for vasomotor and psychological symptoms was inconclusive. Findings for aerobic exercise were inconclusive although there were some examples of beneficial effects on total and vasomotor symptoms. Evidence was very limited for other types of physical activity and impact on physical, sexual and urogenital symptoms.
CONCLUSION: There is some evidence that yoga, and to lesser extent, aerobic exercise may be beneficial for some menopause symptoms, but there is insufficient evidence to recommend a particular form of exercise. Current reviews categorise women on menopause status; broadening this to include ethnicity, income status, employment and other factors will allow better understanding of context for successful interventions.
PURPOSE: To obtain a herpes virus live vaccine by lyophilizing the herpes virus live vaccine with a gas injection until the vaccine attains a specific moisture content to increase the preservation stability thereof. CONSTITUTION: This stable lyophilized herpes virus live vaccine, capable of preferably forming a mixed vaccine with four vaccines by mixing the vaccine with a varicella or a measles vaccine, a mumps vaccine and a rubella vaccine, and containing each of the vaccines in amounts effective for a person immunized with each of the vaccines, is obtained by a gas injection lyophilization by using a lyophilizing process preferably containing a first cycle with a gas injection and a second cycle, for approx. 7-11hr total time of both cycles to contain approx. 0.5-8%, preferably approx. 0.5-2%, approx. 2-5% or approx. 5-8% (as effective subset) moisture content to increase the preservation stability of the above vaccine and enabling the preservation thereof not at (-)20 deg.C (freezer) but at 5 deg.C (refrigerator).